-
公开(公告)号：US12157778B2
公开(公告)日：2024-12-03
申请号：US17146009
申请日：2021-01-11
Applicant: The Regents of the University of California
Inventor： Wei Yao , Ruiwu Liu , Kit S. Lam , Wenwu Xiao , Nancy Lane
IPC: A61K38/07 , A61K31/663 , A61K47/64 , A61P19/10 , C07K5/103
Abstract: The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.
-
公开(公告)号：US20230346960A1
公开(公告)日：2023-11-02
申请号：US18168792
申请日：2023-02-14
Inventor： Alyssa Panitch , Emily Michelle Misnick , Jenny B. Lin , Kit S. Lam , Ruiwu Liu , Dake Hao , Aijun Wang
CPC classification number: A61K47/61 , A61K47/64 , A61K47/60 , A61P9/00 , C07K7/06 , C07K7/08 , A61K38/00
Abstract: The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).
-
公开(公告)号：US11612663B2
公开(公告)日：2023-03-28
申请号：US17062300
申请日：2020-10-02
Inventor： Alyssa Panitch , Emily Michelle Misnick , Jenny B. Lin , Kit S. Lam , Ruiwu Liu , Dake Hao , Aijun Wang
Abstract: The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).
-
公开(公告)号：US10881748B2
公开(公告)日：2021-01-05
申请号：US16595178
申请日：2019-10-07
Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
IPC: A61K49/20 , A61K31/4709 , A61K31/41 , C07D207/273 , A61K31/05 , A61K31/4015 , C07D207/20 , A61K31/4178 , C07D491/052 , C07D207/14 , A61K31/015 , A61K31/353 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/53
Abstract: The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.
-
公开(公告)号：US09561256B2
公开(公告)日：2017-02-07
申请号：US14806398
申请日：2015-07-22
Applicant: The Regents of the University of California
Inventor： Kit S. Lam , Ruiwu Liu , Wei Yao , Nancy Lane
IPC: A61K38/00 , A61P19/08 , A61P19/02 , A61P19/10 , A61K38/10 , A61K38/16 , A61K38/08 , A61K38/06 , A61K38/07 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , A61K31/663 , C07K7/06 , A61K31/66 , C07F9/02 , A61K31/00 , A61K31/661 , A61K47/48 , C07K5/09 , C07K5/103 , C07K5/107 , C07K5/11 , A61K35/28
CPC classification number: C07K5/0821 , A61K31/00 , A61K31/66 , A61K31/661 , A61K31/663 , A61K35/28 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/10 , A61K47/548 , A61K47/64 , C07F9/02 , C07K5/0817 , C07K5/101 , C07K5/1016 , C07K5/1019 , C07K7/06
Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.
Abstract translation: 本发明提供了肽模拟配体的化合物和药物组合物，例如 与双膦酸盐药物缀合的LLP2A，例如 阿仑膦酸盐 本发明的化合物和药物组合物可用于治疗骨质疏松症和促进骨生长，因为它们对间充质干细胞和骨表面上的α4β1整联蛋白的特异性。
-
Patent Agency Ranking
公开(公告)号：US20210401993A1
公开(公告)日：2021-12-30
申请号：US17142026
申请日：2021-01-05
Applicant: The Regents of the University of California
Inventor： Nancy E. Lane , Ruiwu Liu , Wei Yao , Kit S. Lam
Abstract: The present invention provides methods of treating a subject having a primary inflammatory disease or disorder comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, wherein the composition comprising the LLP2A-bisphosphonate conjugate enhances the delivery of mesenchymal stem cells to a site of inflammation. Methods of enhancing an anti-inflammatory or immunomodulatory property of mesenchymal stem cells, comprising administering to a subject in need thereof the mesenchymal stem cells and a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, are also provided.
-
公开(公告)号：US20170174722A1
公开(公告)日：2017-06-22
申请号：US15387380
申请日：2016-12-21
Applicant: The Regents of the University of California
Inventor： Kit S. Lam , Ruiwu Liu , Wei Yao , Nancy Lane
IPC: C07K5/097
CPC classification number: C07K5/0821 , A61K31/00 , A61K31/66 , A61K31/661 , A61K31/663 , A61K35/28 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/10 , A61K47/548 , A61K47/64 , C07F9/02 , C07K5/0817 , C07K5/101 , C07K5/1016 , C07K5/1019 , C07K7/06
Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.
-
公开(公告)号：US20220241227A1
公开(公告)日：2022-08-04
申请号：US17522405
申请日：2021-11-09
Applicant: The Regents of The University of California
Inventor： Yu-Jui Yvonne Wan , Kit S. Lam , Ruiwu Liu
IPC: A61K31/19 , A61K47/58 , A61K31/203 , A61K31/167 , A61K31/192 , A61K31/351 , A61K31/4436 , A61P35/00
Abstract: The present invention provides compositions and methods comprising conjugates with a polymeric backbone, e.g., polyvinyl alcohol (PVA), covalently linked histone deacetylase (HDAC) inhibitors, such as butyrate or propionate, and covalently linked retinoids, such as all-trans retinoic acid (RA). The methods and compositions of the invention are useful for the treatment or prevention of cancer or metabolic diseases in tissues such as the colon or liver.
-
公开(公告)号：US20220133897A1
公开(公告)日：2022-05-05
申请号：US17470976
申请日：2021-09-09
Applicant: The Regents of The University of California
Inventor： Alyssa Panitch , Tima Dehghani , Harkanwalpreet Sodhi , Kit Lam , Ruiwu Liu , Xiaocen Li , Nipavan Chiamvimonvat , Phung N. Thai
Abstract: Provided herein are selectin-binding peptide ligands having both D- and L-amino acids, and peptide conjugates including the provided peptide ligands. The peptide conjugates can include a biopolymer backbone, such as dermatan sulfate, and 33 or fewer peptide ligands conjugated to the biopolymer. Also provided are methods for using the provided peptide conjugates to treat patients suffering from endothelial dysfunction.
-
公开(公告)号：US20210093728A1
公开(公告)日：2021-04-01
申请号：US17062300
申请日：2020-10-02
Inventor： Alyssa Panitch , Emily Michelle Misnick , Jenny B. Lin , Kit S. Lam , Ruiwu Liu , Dake Hao , Aijun Wang
Abstract: The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.022 seconds)
